COMMUNIQUÉS West-GlobeNewswire

Cannabis Wheaton Income Corp. Provides FV Pharma Inc. Facility Development Update

15/05/2018 - 13:30

VANCOUVER, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (TSX.V:CBW) (" Cannabis Wheaton " or the " Company ") is pleased to provide the following development update on the joint [...]

Cutera to Present at Jefferies Global Healthcare Conference

15/05/2018 - 13:30

BRISBANE, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq: CUTR ), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, announced today that James Reinstein, [...]

Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting

15/05/2018 - 13:05

SALT LAKE CITY, May 15, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from eight studies at [...]

XOMA to Present at the UBS Global Healthcare Conference

15/05/2018 - 13:00

EMERYVILLE, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA ), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced that Jim Neal, Chief Executive [...]

Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy

15/05/2018 - 13:00

HOUSTON, May 15, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]

Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates

15/05/2018 - 13:00

Conference call at 8:30 a.m. EDT, Tuesday, May 15, 2018 RUTHERFORD, N.J., May 15, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX ), a leader in enabling precision medicine for oncology through molecular [...]

Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat Conference

15/05/2018 - 12:10

Company to Hold Conference Call at 8:00 am ET Today XEN1101 Pilot TMS-EEG Data Demonstrates Statistically Significant Effect of 20mg Dose versus Baseline (p<0.01) and Greater Effect on TMS-EMG Resting Motor Threshold [...]

Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference

15/05/2018 - 12:05

Company to Hold Conference Call at 8:00 am ET Today Preliminary Phase 1 Clinical Data Support Drug Exposure Levels Higher than Required in Pre-clinical Efficacy Models with Excellent Tolerability and Safety New Pre- [...]

PotNetwork Holdings, Inc. Exceeds $2 Million in Revenues in April 2018, Realizing a 98% Increase Over April 2017

15/05/2018 - 12:00

Reflecting the Company’s Commitment to Excellence in Research, Innovation and Consumer Satisfaction, Exponential Results Continue FT LAUDERDALE, Fla., May 15, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- PotNetwork [...]

Invivoscribe Releases the LymphoTrack Dx TRB Assay as CE-Marked IVD Kit, Completing the NGS Clonality Suite for the MiSeq Platform

15/05/2018 - 12:00

SAN DIEGO, May 15, 2018 (GLOBE NEWSWIRE) -- Invivoscribe Technologies Inc., a global company with decades of experience providing clonality and biomarker test solutions for the fields of oncology and personalized [...]

Transactions in relation to share buyback program

15/05/2018 - 11:13

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

United States Commerce Department Invites ViaDerma to Participate in Official Trade Mission to India

15/05/2018 - 11:00

LOS ANGELES, May 15, 2018 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to announce their participation in the upcoming Beauty & Wellness Executive Service Program , hosted by the [...]

Navamedic ASA: Notice of Annual General Meeting

15/05/2018 - 09:48

The Annual General Meeting in Navamedic ASA will take place on Thursday 7 June 2017 at 14.00 at Felix Konferansesenter, Bryggetorget 3, Oslo. Please find attached the annual report. Notice of the meeting, has been [...]

Update: Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 30, 2018

15/05/2018 - 09:47

Message from the CEO During the past year, IBT passed the most important milestones in the company's history. The company's drug candidate, IBP-9414, which we believe will prevent necrotizing enterocolitis, has [...]

LIDDS broadens the scope of its technology platform by verifying NanoZolid® as subcutaneous depot for systemic delivery

15/05/2018 - 08:31

UPPSALA, SWEDEN - LIDDS AB (publ) is today unveiling new animal data which demonstrates that subcutaneously injected NanoZolid® can act as a depot for systemic delivery of pharmaceutically active drugs. A two week [...]

Navamedic ASA: Notice of Annual General Meeting

15/05/2018 - 08:02

The Annual General Meeting in Navamedic ASA will take place on Thursday 7 June 2017 at 14.00 at Felix Konferansesenter, Bryggetorget 3, Oslo. Please find attached the annual report. Notice of the meeting, has been [...]

Shire plc : Rule 2.9 Announcement

15/05/2018 - 08:01

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 15 May 2018 Shire [...]

PCI Biotech to present at BioEquity Europe

15/05/2018 - 08:00

Oslo, Norway, May 15, 2018 PCI Biotech (OSE: PCIB ), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present the Company at [...]

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 30, 2018

15/05/2018 - 08:00

Message from the CEO During the past year, IBT passed the most important milestones in the company's history. The company's drug candidate, IBP-9414, which we believe will prevent necrotizing enterocolitis, has [...]